Skip to main content
Erschienen in: Clinical Research in Cardiology 2/2019

26.07.2018 | Original Paper

T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF

verfasst von: Aurelija Abraityte, Pål Aukrust, Lei Kou, Inder S. Anand, James Young, John J. V. Mcmurray, Dirk J. van Veldhuisen, Lars Gullestad, Thor Ueland

Erschienen in: Clinical Research in Cardiology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Activated leukocytes may contribute to the development and progression of heart failure (HF). We investigated the predictive value of circulating levels of stable and readily detectable markers reflecting both monocyte/macrophage and T-cell activity, on clinical outcomes in HF patients with reduced ejection fraction (HFrEF).

Methods

The association between baseline plasma levels of soluble CD163 (sCD163), macrophage migration inhibitory factor (MIF), granulysin, soluble interleukin-2 receptor (sIL-2R), and activated leukocyte cell adhesion molecule (ALCAM) and the primary endpoint of death from any cause or first hospitalization for worsening of HF was evaluated using multivariable Cox proportional hazard models in 1541 patients with systolic HF and mild to moderate anemia, enrolled in the Reduction of Events by darbepoetin alfa in Heart Failure (RED-HF) trial. Modifying effects and interaction with darbepoetin alfa treatment were also assessed.

Results

All leukocyte markers, except granulysin, were associated with the primary outcome and all-cause death in univariate analysis (all p < 0.01) and remained significantly associated in multivariable analysis adjusting for conventional clinical variables (e.g. age, gender, BMI, NYHA class, creatinine, LVEF, etiology) and CRP. However, after final adjustment for TnT and NT-proBNP no associations were found with outcomes. No interaction with darbepoetin alpha treatment was observed for any marker.

Conclusions

Leukocyte activation markers sCD163, MIF, sIL-2R, and ALCAM were associated with adverse outcome in patients with HFrEF, but add little as prognostic markers on top of established biochemical risk markers.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
11.
14.
Zurück zum Zitat Hintz KA, Rassias AJ, Wardwell K, Moss ML, Morganelli PM, Pioli PA, Givan AL, Wallace PK, Yeager MP, Guyre PM (2002) Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocyte hemoglobin scavenger receptor CD163. J Leukoc Biol 72(4):711–717PubMed Hintz KA, Rassias AJ, Wardwell K, Moss ML, Morganelli PM, Pioli PA, Givan AL, Wallace PK, Yeager MP, Guyre PM (2002) Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocyte hemoglobin scavenger receptor CD163. J Leukoc Biol 72(4):711–717PubMed
15.
Zurück zum Zitat Calandra T, Bernhagen J, Mitchell RA, Bucala R (1994) The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179(6):1895–1902CrossRefPubMed Calandra T, Bernhagen J, Mitchell RA, Bucala R (1994) The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179(6):1895–1902CrossRefPubMed
16.
Zurück zum Zitat Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL (1985) Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135(5):3172–3177PubMed Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL (1985) Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135(5):3172–3177PubMed
17.
Zurück zum Zitat Bowen MA, Patel DD, Li X, Modrell B, Malacko AR, Wang WC, Marquardt H, Neubauer M, Pesando JM, Francke U et al (1995) Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med 181(6):2213–2220CrossRefPubMed Bowen MA, Patel DD, Li X, Modrell B, Malacko AR, Wang WC, Marquardt H, Neubauer M, Pesando JM, Francke U et al (1995) Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med 181(6):2213–2220CrossRefPubMed
19.
Zurück zum Zitat Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O’Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ, Committees R-H, Investigators R-H (2013) Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368(13):1210–1219. https://doi.org/10.1056/NEJMoa1214865 CrossRefPubMed Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O’Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ, Committees R-H, Investigators R-H (2013) Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368(13):1210–1219. https://​doi.​org/​10.​1056/​NEJMoa1214865 CrossRefPubMed
20.
Zurück zum Zitat McMurray JJ, Anand IS, Diaz R, Maggioni AP, O’Connor C, Pfeffer MA, Polu KR, Solomon SD, Sun Y, Swedberg K, Tendera M, van Veldhuisen DJ, Wasserman SM, Young JB (2009) Design of the reduction of events with darbepoetin alfa in heart failure (RED-HF): a phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 11(8):795–801. https://doi.org/10.1093/eurjhf/hfp098 CrossRefPubMed McMurray JJ, Anand IS, Diaz R, Maggioni AP, O’Connor C, Pfeffer MA, Polu KR, Solomon SD, Sun Y, Swedberg K, Tendera M, van Veldhuisen DJ, Wasserman SM, Young JB (2009) Design of the reduction of events with darbepoetin alfa in heart failure (RED-HF): a phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 11(8):795–801. https://​doi.​org/​10.​1093/​eurjhf/​hfp098 CrossRefPubMed
21.
Zurück zum Zitat McMurray JJ, Anand IS, Diaz R, Maggioni AP, O’Connor C, Pfeffer MA, Solomon SD, Tendera M, van Veldhuisen DJ, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB, Investigators R-HC (2013) Baseline characteristics of patients in the reduction of events with darbepoetin alfa in heart failure trial (RED-HF). Eur J Heart Fail 15(3):334–341. https://doi.org/10.1093/eurjhf/hfs204 CrossRefPubMedPubMedCentral McMurray JJ, Anand IS, Diaz R, Maggioni AP, O’Connor C, Pfeffer MA, Solomon SD, Tendera M, van Veldhuisen DJ, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB, Investigators R-HC (2013) Baseline characteristics of patients in the reduction of events with darbepoetin alfa in heart failure trial (RED-HF). Eur J Heart Fail 15(3):334–341. https://​doi.​org/​10.​1093/​eurjhf/​hfs204 CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Gullestad L, Ueland T, Brunsvig A, Kjekshus J, Simonsen S, Froland SS, Aukrust P (2001) Effect of metoprolol on cytokine levels in chronic heart failure—a substudy in the metoprolol controlled-release randomised intervention trial in heart failure (MERIT-HF). Am Heart J 141(3):418–421. https://doi.org/10.1067/mhj.2001.112785 CrossRefPubMed Gullestad L, Ueland T, Brunsvig A, Kjekshus J, Simonsen S, Froland SS, Aukrust P (2001) Effect of metoprolol on cytokine levels in chronic heart failure—a substudy in the metoprolol controlled-release randomised intervention trial in heart failure (MERIT-HF). Am Heart J 141(3):418–421. https://​doi.​org/​10.​1067/​mhj.​2001.​112785 CrossRefPubMed
24.
Zurück zum Zitat Limas CJ, Hasikidis C, Iakovou J, Kroupis C, Haidaroglou A, Cokkinos DV (2003) Prognostic significance of soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. Eur J Clin Invest 33(6):443–448CrossRefPubMed Limas CJ, Hasikidis C, Iakovou J, Kroupis C, Haidaroglou A, Cokkinos DV (2003) Prognostic significance of soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. Eur J Clin Invest 33(6):443–448CrossRefPubMed
27.
Zurück zum Zitat O’Meara E, Murphy C, McMurray JJ (2004) Anemia and heart failure. Curr Heart Fail Rep 1(4):176–182CrossRefPubMed O’Meara E, Murphy C, McMurray JJ (2004) Anemia and heart failure. Curr Heart Fail Rep 1(4):176–182CrossRefPubMed
31.
Zurück zum Zitat Martiney JA, Sherry B, Metz CN, Espinoza M, Ferrer AS, Calandra T, Broxmeyer HE, Bucala R (2000) Macrophage migration inhibitory factor release by macrophages after ingestion of Plasmodium chabaudi-infected erythrocytes: possible role in the pathogenesis of malarial anemia. Infect Immun 68(4):2259–2267CrossRefPubMedPubMedCentral Martiney JA, Sherry B, Metz CN, Espinoza M, Ferrer AS, Calandra T, Broxmeyer HE, Bucala R (2000) Macrophage migration inhibitory factor release by macrophages after ingestion of Plasmodium chabaudi-infected erythrocytes: possible role in the pathogenesis of malarial anemia. Infect Immun 68(4):2259–2267CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Pereira R, Costa E, Goncalves M, Miranda V, do Sameiro Faria M, Quintanilha A, Belo L, Lima M, Santos-Silva A (2010) Neutrophil and monocyte activation in chronic kidney disease patients under hemodialysis and its relationship with resistance to recombinant human erythropoietin and to the hemodialysis procedure. Hemodial Int Symp Home Hemodial 14(3):295–301. https://doi.org/10.1111/j.1542-4758.2010.00450.x CrossRef Pereira R, Costa E, Goncalves M, Miranda V, do Sameiro Faria M, Quintanilha A, Belo L, Lima M, Santos-Silva A (2010) Neutrophil and monocyte activation in chronic kidney disease patients under hemodialysis and its relationship with resistance to recombinant human erythropoietin and to the hemodialysis procedure. Hemodial Int Symp Home Hemodial 14(3):295–301. https://​doi.​org/​10.​1111/​j.​1542-4758.​2010.​00450.​x CrossRef
34.
Zurück zum Zitat Cooper AC, Breen CP, Vyas B, Ochola J, Kemeny DM, Macdougall IC (2003) Poor response to recombinant erythropoietin is associated with loss of T-lymphocyte CD28 expression and altered interleukin-10 production. Nephrol Dialysis Transplant 18(1):133–140CrossRef Cooper AC, Breen CP, Vyas B, Ochola J, Kemeny DM, Macdougall IC (2003) Poor response to recombinant erythropoietin is associated with loss of T-lymphocyte CD28 expression and altered interleukin-10 production. Nephrol Dialysis Transplant 18(1):133–140CrossRef
36.
Zurück zum Zitat Reiner AP, Lange EM, Jenny NS, Chaves PH, Ellis J, Li J, Walston J, Lange LA, Cushman M, Tracy RP (2013) Soluble CD14: genomewide association analysis and relationship to cardiovascular risk and mortality in older adults. Arteriosclerosis Thromb Vascular Biol 33 (1):158–164. https://doi.org/10.1161/ATVBAHA.112.300421 CrossRef Reiner AP, Lange EM, Jenny NS, Chaves PH, Ellis J, Li J, Walston J, Lange LA, Cushman M, Tracy RP (2013) Soluble CD14: genomewide association analysis and relationship to cardiovascular risk and mortality in older adults. Arteriosclerosis Thromb Vascular Biol 33 (1):158–164. https://​doi.​org/​10.​1161/​ATVBAHA.​112.​300421 CrossRef
Metadaten
Titel
T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF
verfasst von
Aurelija Abraityte
Pål Aukrust
Lei Kou
Inder S. Anand
James Young
John J. V. Mcmurray
Dirk J. van Veldhuisen
Lars Gullestad
Thor Ueland
Publikationsdatum
26.07.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Research in Cardiology / Ausgabe 2/2019
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-018-1331-2

Weitere Artikel der Ausgabe 2/2019

Clinical Research in Cardiology 2/2019 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.